Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Inflamm Regen
Autors principals: Han, Nanumi, Baghdadi, Muhammad, Ishikawa, Kozo, Endo, Hiraku, Kobayashi, Takuto, Wada, Haruka, Imafuku, Keisuke, Hata, Hiroo, Seino, Ken-ichiro
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836392/
https://ncbi.nlm.nih.gov/pubmed/29515691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41232-018-0060-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars